Hot Investor Mandate: Family Office Investment Vehicle Seeks Early-Stage Therapeutic Opportunities with Strong Focus on Rare Disease

21 Nov

A family-run investment and commercialization vehicle invests in early-stage life science and technologies. The group is flexible in terms of deal structure with past investments ranging from minority commitments in a funding round to in-licensing entire therapeutic programs.

The firm specializes in therapeutic opportunities and has a particular focus on rare diseases. The group is most interested in indications where the pathophysiology is well-understood, the developmental pathway is straight-forward, and there is a clear unmet medical need. Opportunities that are de-risked in some way, such as reformulation or repurposing plays, are also considered attractive.

The firm has a strong preference for experienced management teams with proven tracks records of driving value.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Taiwan-Based VC Firm Actively Seeks Cross Border Investment Opportunities in Medical Devices with Large Market Potential

21 Nov

A venture capital firm based in Taiwan solely invests in early stage medical technology ventures. The firm currently manages a USD 100 million fund. The firm focuses on Series A and B rounds and looks to allocate USD 500K to 3 million per round with reserved follow-on investments. The firm will target companies in Taiwan, Israel, and the US. The firm is actively seeking new investments.

The firm looks to invest in innovative medical devices. The firm seeks breakthrough products that are clearly differentiated and superior to existing products. The firm is opportunistic in terms of subsectors and will consider devices in Class I, II, and III. The firm is indication agnostic but only seeks large market opportunities of at least $500 million in targeted annual revenue.

The firm seeks a strong and experienced management team and typically seeks board representation post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Asia Based PE/VC Firm with Evergreen Fund Invests Up to $15M in Global Breakthrough Life Science Companies

21 Nov

A Life Science focused private equity and venture capital firm based in Asia manages an evergreen fund, and generally makes longer term investments than a typical VC.  The firm does not make seed investments, but is interested in both early stage venture capital investments and late stage companies seeking growth and expansion capital. Typically, the firm invests USD 5-15 million per opportunity. The firm can invest globally and is actively seeking new investment opportunities.

The firm seeks to invest in breakthrough healthcare biotech, medical devices, diagnostics, healthcare IT, and biorenewable and bioindustrial technologies. The firm is open to a wide range of technologies including novel techniques such as stem cells and genomics, and will consider investing in any area of medicine. The firm prefers to invest in technologies that have attained clinical validation.

The firm seeks a strong and experienced management team. The firm may take a board seat on a case by case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: VC Firm with US and Canada Operations Invests in Early-Stage Medical Devices and Diagnostics Companies Globally

21 Nov

A venture capital firm with offices in USA and Canada is making investments out of its vintage 2017, fourth fund and is exclusively focused on supporting entrepreneurs commercializing advanced materials and advanced material process innovations within four verticals: energy, electronics, health, and sustainability. The firm typically makes initial investments in the $1M-$4M range and up to $8M over the life of the investment (more or less may be initially invested depending on the deal). The firm prefers to lead deals but will also participate in a syndicate as a co-investor. The firm has strategic LP relationships in Asia, Europe, the Middle East, and North America and invests globally.

Within healthcare, the firm is interested in medical devices and diagnostics whose underlying technology is enabled by advanced materials or advanced material process innovations. The firm has a particular interest in 3D bioprinting, diagnostics and genomics/proteomics R&D applications. The firm does not make investments in pharmaceuticals/therapeutics. Past investments have included a manufacturer of semiconductor radiation detectors enabling a new generation of detection and imaging equipment, a company developing a disruptive 3D bioprinting platform, and a company developing functional surfaces with anti-microbial and anti-fouling properties.

The firm prefers to work with experienced management teams, but is open to working with less experienced entrepreneurs or incomplete management teams given the firm can add value through corporate strategy and operational experience to help accelerate development. The firm prefers to invest in revenue-generating companies but is open to evaluating pre-revenue companies as well. The firm typically seeks a board seat along with investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Announcing RESI Asia Innovation Challenge Finalists

31 Oct

By Karen Deyo, Senior Investor Research Analyst, LSN

We are excited to announce the finalists in the Innovation Challenge at both RESI Shanghai, taking place on Tuesday, Nov. 12th and RESI Taipei, taking place on Thursday, Nov. 14th. These companies will present posters in the Exhibit Hall, where RESI attendees can see their innovative technologies and ‘invest’ their ‘RESI cash’ tokens to vote for their favorite companies. The three companies with the most ‘invested’ by the end of the day will win prizes.

In addition to presenting posters, for the first time, each company will also get an opportunity to pitch to a panel of investors and industry experts, who will ask questions and provide feedback. Below are the pitching schedules for the selected companies – make sure to stop by and watch these amazing companies pitch!

RESI Shanghai Innovation & Pitch Challenge

RESI Taipei Innovation & Pitch Challenge

What is Partnering? – The Importance of Partnering in the Life Sciences

31 Oct

By Lucy Parkinson, VP of Investor Research, LSN

At LSN, we talk a lot about life science partnering meetings: our goal is to make RESI Partnering as productive for our RESI attendees as possible. LSN founded RESI because we had learned that while there are many other partnering events in the life science world, the experience was often lacking and we thought we could substantially improve it (and we have). Partnering is so instinctive for us that we rarely stop to think about what partnering is, and why it’s so important in the life science sector in particular: you might say partnering is just in our DNA.

As we’ve brought RESI to Asia, we’ve learned about how Asia has a different style of doing business conferences, where partnering is much less widely known. We therefore wanted to make a ground-up introduction to life science partnering.

Why Partnering, Why In Life Science?

Partnering was originally driven by the needs of big pharma companies. These firms have an intense focus on developing their future pipelines, and this often means looking for external assets that they could license in to bolster their strategies as existing products move toward the end of patent life. Pharmas draw up specific maps of the technologies that they need, and have sophisticated teams that look externally for these assets.

The life sciences industry is as much a people business as it is a technology business. When a pharma company licenses an asset, that often means embarking on years of co-development work in which the pharma and the startup share resources and expertise to bring the product through clinical trials. It’s therefore essential to meet people face to face, get to know how they work, and learn to trust them. However, networking in a conference hall isn’t the best way to find the people who are developing those specific technologies that are needed.

Partnering events offered pharma BD staff a way to meet lots of drug development entrepreneurs in one place, by using an online system to receive meeting requests and select in advance who they wanted to connect with at the event. This offered much more efficiency than networking, and a much more personal connection than watching a startup give a pitch on a stage.

Since its origin, partnering events have also served other investors and life science players as well, such as CROs and other service providers who can use the events to connect with new customers who need their particular expertise.

What happens at a partnering event?

When you register for a partnering event like RESI, you will be added to an online meeting schedule system that you can use to plan your day.  You can use this system to send messages to other attendees and ask them to meet with you.  You will also receive messages from other attendees, and can decide whether to accept or decline their meeting requests.  In this way, every attendee manages their own schedule and decides for themself who they would like to meet.

If a meeting request is accepted, the system will find a time and location for the meeting.  The locations will be numbered tables or booths where you can sit down and talk to your meeting partner, usually for 30 minutes. It’s therefore possible to have in-depth conversations about your business with lots of people in one day.

If you have other plans throughout the day, such as a presentation or panel session you wish to attend, the partnering system will allow you to mark yourself as unavailable for meetings at those times.  Be sure to set your availability before you make any meeting requests.

How did RESI change partnering?

While partnering is generally more efficient than networking, it is still often hard to find meeting partners who are a good fit for your business. For example, if you are an entrepreneur developing a new cell therapy product in the cardiovascular space, it might be difficult to identify investors who are interested in this type of technology. You might inadvertently send requests to people who aren’t a relevant fit, and receive a poor return on your efforts. From the investor or pharma point of view, it can be very challenging to receive many unsuitable meeting requests at an event, and time-consuming to filter through them for good fits.

The other big challenge for entrepreneurs attending a partnering event is simply finding real investors who are ready to allocate. At many events, active investors are thin on the ground, and you might end up meeting someone who claims to be an ‘investor’ but is really just a broker or investment banker.

RESI’s key insights are thus: in life science, there are buyers (typically investors, big pharma and other corporations that invest strategically such as medical device corporations), and there are sellers (scientist-entrepreneurs and early stage companies). Good partnering depends on both of these sides having fully developed profiles that can be filtered to look for relevant fits.

The second key insight is that it takes a dedicated team to find investors, vet investors, invite them to the event, and profile their requirements. LSN’s Investor Research team is dedicated to speaking with investors and pharma/strategic investors worldwide and learning what they are looking for. Most RESI events have a 1:1 ratio of startups to investors, thereby maximizing an entreprenur’s chance of getting investor meetings.

The third key insight is that the life sciences industry is an extremely granular business. Everyone has their own niche of expertise and technological savvy, from antibodies to robotics to medical AI. In addition to technology type, stage of product development is also an extremely significant variable. There are some investors who specialize in making investments in preclinical or prototype-stage companies; meanwhile, others prefer to only invest after the company’s product has proven its clinical safety and/or efficacy. It’s therefore not enough to simply bring investors to an event, or to offer startups a chance to send messages to them. LSN’s Investor Research team prepopulate investor profiles with information on what the investor is looking for and what their criteria are, in order to help startups identify the investors who are truly a fit for them.

So how does that affect entrepreneurs?  It means you are more likely to meet the right people. It means that when you sit down across from an investor, you already know you have a good fit – they’re interested in technologies like yours, and they have money to invest in people like you. For hundreds of RESI attendees, these initial meetings have eventually led to receiving an investment.

As we bring RESI Partnering to Asia for the first time, we hope to continue this success and make many more new connections happen.

Video: The Redefining Early Stage Investments (RESI) Conference

31 Oct

By Nono Hu, Director of Marketing, LSN

The Redefining Early Stage Investments (RESI) Conference presents many great opportunities for life science entrepreneurs looking for investors. RESI offers entrepreneurs the opportunity to engage in 1-on-1 meetings – up to 16 scheduled 1-on-1’s in a day and many additional ad-hoc meetings!

Life Science Nation (LSN) isn’t just RESI though. This video provides an overview of how RESI fits together with LSN’s two other services, the LSN Investor Platform and LSN Company Platform, and also with Boston Innovation Capital (BIC), a registered broker dealer who is a wholly owned subsidiary of LSN.

Come learn about how attending RESI and utilizing our other services can help you find the investors you’re looking for in the video below! Also, be sure to register for RESI Asia for a chance to experience how RESI can help you make the connections you need to get the investment you need.